Pomalyst® is the newest oral immunomodulatory drug (IMiD®). Approved by the FDA in 2013, Pomalyst is chemically related to thalidomide and lenalidomide, which was approved by the FDA in 2006, but Pomalyst has been enhanced to be more effective.
The U.S. Food and Drug Administration (FDA) approved Pomalyst® (pomalidomide) on February 8, 2013, to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.
Like lenalidomide, pomalidomide is an immunomodulatory derivative (IMiD) of thalidomide. Approved by the FDA in 2013, alone and in combination with other drugs, it is showing clinical activity and is well-tolerated in patients who have relapsed after multiple prior therapies and are refractory to both lenalidomide and bortezomib.